By a News Reporter-Staff News Editor at Life Science Weekly — According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Brainstorm Cell Therapeutics Inc. (Form D) was posted on July 1, 2014.
The SIC code for this company is 2836, Biological Products, (No Diagnostic Substances).
There was one document filed with this form. The SEC file number is 0001144204-14-040621.
The contact information for this company is 605 THIRD AVENUE, 34TH FLOOR, NEW YORK NY 10158, 646-666-3188.
Our editors provided additional information about Form D: Companies selling securities in reliance on a Regulation D exemption or a Section 4(6) exemption from the registration provisions of the ’33 Act must file a Form D as notice of such a sale. The form must be filed no later than 15 days after the first sale of securities. For additional information on Regulation D and Section 4(6) offerings, ask for a copy of the Regulation and the pamphlet entitled: “Q & A: Small Business and the SEC” from the Commission’s Publications Unit or see the Small Business Section of the Commission’s Web Site.
A U.S. Securities and Exchange Commission filing is a formal document or financial statement submitted to the SEC by publicly-traded companies.
For additional information on this SEC filing see: http://www.sec.gov/Archives/edgar/data/1137883/0001144204-14-040621-index.html.
Keywords for this news article include: SEC Filing, Biological Products, (No Diagnostic Substances), Brainstorm Cell Therapeutics Inc..
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
